Clinical Roundup Positive topline results announced from phase I study of Lymphir + pembrolizumab in r/r gynecologic cancers March 13, 2026Vol.52 No.10
Clinical Roundup Novel antibody blocks Epstein-Barr virus, Fred Hutch study finds March 13, 2026Vol.52 No.10
Clinical Roundup Growing number of U.S. adults wrongly think vaping is more harmful than smoking cigarettes, study shows March 13, 2026Vol.52 No.10
Drugs & Targets FDA approves Tecvayli + Darzalez Faspro for r/r MM as second line treatment March 13, 2026Vol.52 No.10
Drugs & Targets Ipsen voluntarily withdraws Tazverik in follicular lymphoma and epithelioid sarcoma March 13, 2026Vol.52 No.10
News Analysis GRAIL presses on with Galleri test despite missed primary endpoint in pivotal studyWhere GRAIL sees signals of benefit in the subgroups, screening experts see signs of overdiagnosis March 06, 2026Vol.52 No.09By Jacquelyn Cobb and Sara Willa Ernst
Conversation with The Cancer Letter GRAIL’s Megan Hall: “I think we can be confident that there is clinical benefit to implementing this technology. And I think that’s really hard to argue with.”Mainstream epidemiologists beg to differ March 06, 2026Vol.52 No.09By Jacquelyn Cobb and Sara Willa Ernst
Conversation with The Cancer Letter NCI’s Philip Castle on NHS-Galleri results: “I’m sorry that it didn’t work, but it keeps the national conversation going.”Castle is “disappointed” by Galleri results but not discouraged by implications for MCDs March 06, 2026Vol.52 No.09By Jacquelyn Cobb and Sara Willa Ernst
Cancer Policy Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members March 06, 2026Vol.52 No.09By Claire Marie Porter and Sara Willa Ernst
Cancer Policy House member introduces bill to increase funding for MCD testing of firefighters March 06, 2026Vol.52 No.09By Sara Willa Ernst
